452 related articles for article (PubMed ID: 27557833)
1. Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy.
Chasen M; Urban L; Schnadig I; Rapoport B; Powers D; Arora S; Navari R; Schwartzberg L; Gridelli C
Support Care Cancer; 2017 Jan; 25(1):85-92. PubMed ID: 27557833
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
[TBL] [Abstract][Full Text] [Related]
3. Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC).
Rapoport B; Chua D; Poma A; Arora S; Wang Y; Fein LE
Support Care Cancer; 2015 Nov; 23(11):3281-8. PubMed ID: 25940030
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy.
Hesketh PJ; Schnadig ID; Schwartzberg LS; Modiano MR; Jordan K; Arora S; Powers D; Aapro M
Cancer; 2016 Aug; 122(15):2418-25. PubMed ID: 27176138
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials.
Rapoport BL; Chasen MR; Gridelli C; Urban L; Modiano MR; Schnadig ID; Poma A; Arora S; Kansra V; Schwartzberg LS; Navari RM
Lancet Oncol; 2015 Sep; 16(9):1079-1089. PubMed ID: 26272769
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial.
Schwartzberg LS; Modiano MR; Rapoport BL; Chasen MR; Gridelli C; Urban L; Poma A; Arora S; Navari RM; Schnadig ID
Lancet Oncol; 2015 Sep; 16(9):1071-1078. PubMed ID: 26272768
[TBL] [Abstract][Full Text] [Related]
7. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
Piechotta V; Adams A; Haque M; Scheckel B; Kreuzberger N; Monsef I; Jordan K; Kuhr K; Skoetz N
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012775. PubMed ID: 34784425
[TBL] [Abstract][Full Text] [Related]
8. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.
Lindley C; Goodin S; McCune J; Kane M; Amamoo MA; Shord S; Pham T; Yowell S; Laliberte K; Schell M; Bernard S; Socinski MA
Am J Clin Oncol; 2005 Jun; 28(3):270-6. PubMed ID: 15923800
[TBL] [Abstract][Full Text] [Related]
9. Analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting with moderately and highly emetogenic chemotherapy.
Molassiotis A; Nguyen AM; Rittenberg CN; Makalinao A; Carides A
Future Oncol; 2013 Oct; 9(10):1443-50. PubMed ID: 23987791
[TBL] [Abstract][Full Text] [Related]
10. Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC).
Hesketh PJ; Warr DG; Street JC; Carides AD
Support Care Cancer; 2011 Sep; 19(9):1297-302. PubMed ID: 20623144
[TBL] [Abstract][Full Text] [Related]
11. Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK
Bošnjak SM; Gralla RJ; Schwartzberg L
Support Care Cancer; 2017 May; 25(5):1661-1671. PubMed ID: 28108820
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy.
Ithimakin S; Theeratrakul P; Laocharoenkiat A; Nimmannit A; Akewanlop C; Soparattanapaisarn N; Techawattanawanna S; Korphaisarn K; Danchaivijitr P
Support Care Cancer; 2020 Nov; 28(11):5335-5342. PubMed ID: 32128615
[TBL] [Abstract][Full Text] [Related]
14. Rolapitant: An NK-1 Receptor Antagonist for the Prevention of Chemotherapy- Induced Nausea and Vomiting.
Rapoport BL
Rev Recent Clin Trials; 2017; 12(3):193-201. PubMed ID: 28393710
[TBL] [Abstract][Full Text] [Related]
15. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
[TBL] [Abstract][Full Text] [Related]
16. Rolapitant for the prevention of delayed nausea and vomiting over initial and repeat courses of emetogenic chemotherapy.
Rapoport B; van Eeden R; Smit T
Expert Rev Clin Pharmacol; 2017 Jan; 10(1):17-29. PubMed ID: 27894202
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types.
Kim JE; Jang JS; Kim JW; Sung YL; Cho CH; Lee MA; Kim DJ; Ahn MJ; Lee KY; Sym SJ; Lim MC; Jung H; Cho EK; Min KW
Support Care Cancer; 2017 Mar; 25(3):801-809. PubMed ID: 27826874
[TBL] [Abstract][Full Text] [Related]
18. Rolapitant: A Review in Chemotherapy-Induced Nausea and Vomiting.
Heo YA; Deeks ED
Drugs; 2017 Oct; 77(15):1687-1694. PubMed ID: 28929404
[TBL] [Abstract][Full Text] [Related]
19. Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy.
Gridelli C; Haiderali AM; Russo MW; Blackburn LM; Lykopoulos K
Support Care Cancer; 2010 Nov; 18(11):1437-44. PubMed ID: 19882176
[TBL] [Abstract][Full Text] [Related]
20. Control of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimens.
Kubota K; Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T
Support Care Cancer; 2016 Sep; 24(9):4025-33. PubMed ID: 27129842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
